PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.44%
EBIT growth 50-75% of AVXL's 26.75%. Martin Whitman would suspect suboptimal resource allocation.
14.44%
Operating income growth at 50-75% of AVXL's 26.75%. Martin Whitman would doubt the firm’s ability to compete efficiently.
12.51%
Net income growth under 50% of AVXL's 25.65%. Michael Burry would suspect the firm is falling well behind a key competitor.
12.37%
EPS growth under 50% of AVXL's 26.32%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
12.37%
Diluted EPS growth under 50% of AVXL's 26.32%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.24%
OCF growth under 50% of AVXL's 16.02%. Michael Burry might suspect questionable revenue recognition or rising costs.
1.24%
FCF growth under 50% of AVXL's 23.96%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.48%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-6.48%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-6.48%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-180.68%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-180.68%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-180.68%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-183.69%
Negative equity/share CAGR over 10 years while AVXL stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-183.69%
Negative 5Y equity/share growth while AVXL is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-183.69%
Negative 3Y equity/share growth while AVXL is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.05%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-17.69%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
7.69%
Debt shrinking faster vs. AVXL's 237.50%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
175.10%
We expand SG&A while AVXL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.